Table 1.
Characteristics of patients and tumors.
| Characteristics | Non-BCR N = 66 | BCR N = 27 | P |
|---|---|---|---|
| Age, mean ± SD, years | 74.3 ± 6.9 | 72.4 ± 9.5 | 0.054 |
| Initial PSA level, mean ± SD, ng/ml | 36.1 ± 52.4 | 84.2 ± 73.2 | 0.032 |
| Pre-radiotherapy PSA level, mean ± SD | 2.7 ± 7.8 | 26.4 ± 76.3 | 0.000 |
| Gleason score group | 0.069 | ||
| Group 1 | 14(21.2) | 3(11.1) | |
| Group 2 | 18(27.3) | 4(14.8) | |
| Group 3 | 9(13.6) | 2(7.4) | |
| Group 4 | 12(18.2) | 7(25.9) | |
| Group 5 | 13(19.7) | 11(40.7) | |
| NCCN risk | 0.010 | ||
| Low | 6(9.1) | 0(0) | |
| Intermediate | 20(30.3) | 1(3.7) | |
| High | 34(51.5) | 20(74.1) | |
| Very high | 6(9.1) | 6(22.2) | |
| T stage | 0.698 | ||
| T1 | 2(3.0) | 0(0) | |
| T2 | 44(66.7) | 9(33.3) | |
| T3 | 17(25.8) | 15(55.6) | |
| T4 | 3(4.5) | 3(11.1) |
Data show number of patients (%) unless otherwise indicated. BCR, biochemical recurrence; PSA, prostate-specific antigen; NCCN, National Comprehensive Cancer Network.